Biomarin Pharmaceutical Inc. plans to divest its pioneering gene therapy for hemophilia, Roctavian (valoctocogene roxaparvovec), and remove what had been considered a potential blockbuster from the portfolio in order to grow the company. Read More
An examination of X-ray and MRI scans of 518 patients before and after treatment with Levicept Ltd.’s Levi-04 has shown that, in addition to providing significant analgesia, the selective neurotrophin-3 inhibitor may have a disease-modifying effect in osteoarthritis of the knee. Read More
Hanmi Pharmaceutical Co. Ltd. announced Oct. 27 that its glucagon-like peptide-1 receptor agonist, efpeglenatide (HM-11260C), met the co-primary endpoints in a phase III study of obese adults without diabetes.
Maplight Therapeutics Inc.’s pricing of a $258.9 million financing this week revived the debate over whether targeting the M1 as well as the M4 muscarinic receptor – as Bristol Myers Squibb Co. does with U.S. FDA-approved Cobenfy (xanomeline and trospium chloride) for schizophrenia – is a better strategy than going after M4 alone. Read More
Zag Bio Inc. came out of stealth mode with $80 million in funding so far, including a recently closed series A financing, to develop its platform for autoimmune diseases using drugs targeted to the thymus where thymic regulatory cells are produced. Read More
What trends in life sciences have defined the last three decades? BioWorld Editor Nuala Moran picks monoclonal antibodies as the most significant. “They are the cornerstone around which medical biotechnology as a sector has been built.” Read More
Clinical updates, including data readouts and publications: BMS, Bridgebio, Cabaletta, Cristcot, Halda, Innovent, Intellia, ITM, Kyverna, J&J, Levicept, Sobi, Xencor, Zenas. Read More
Biopharma happenings, including deals and partnerships, and other news in brief: Enable Injections, Grand Life, GSK, Hyloris, Incyte, Kadimastem, NLS, Organon, Syndivia, Targetgene. Read More
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Bayer, Biogen, Cellectar, Eisai, Merck, Oncoc4, Revolution, Syndax, Zenith. Read More
